Wenn, K
Tomala, L
Wilop, S
Vankann, L
Hasenbank, C
Frank, O
Hochhaus, A
Giles, F J
Lange, T
Müller, M C
Koschmieder, S
Beier, F
Ziegler, P
Brümmendorf, T H
Article History
First Online: 15 September 2015
Competing interests
: SW has an advisory role for Astellas, Merck and Janssen, he receives research funding from Enceladus and travel is sponsored by Merck and Celgene. OF is a Novartis employee. AH receives research funding from Novartis, BMS, Ariad, Pfizer and MSD. FJG is a consultant for Novartis and receives research funding by Novartis. TL receives honoraria from Novartis, BMS, Pfizer and Ariad and research funding from Novartis. MCM receives honoraria and research funding from Ariad, BMS and Novartis. SK is a consultant and member on an entity’s Board of Directors or advisory committees for Novartis and receives honoraria and research funding by Novartis. THB is a consultant and receives honoraria from Ariad, BMS, Novartis and Pfizer, he holds patents and royalties at Novartis and receives research funding from Novartis. The remaining authors declare no conflict of interest.